SAN FRANCISCO, CA / ACCESS Newswire / November 19, 2025 / IVI RMA North America, one of the world's most influential fertility networks, has entered into a multi-year exclusive agreement with Sapyen to incorporate home-based male fertility testing.
The move reflects a broader shift among major fertility networks toward integrating remote diagnostics that can withstand laboratory scrutiny.
Male fertility evaluation has long been structured around the immediate delivery of samples to a laboratory, a logistical requirement that has limited access and shaped the patient experience for decades.
While consumer demand for at-home testing has grown, most options on the market rely on predicted motility or indirect scoring models-approaches that offer convenience but fall short of the methods used in clinical decision-making.
Sapyen's model differs in a material way. The company's patent-pending preservation liquid, SPX72™, preserves sperm viability for up to 72 hours, enabling samples collected at home to be transported to IVF-grade laboratories for analysis using WHO-aligned techniques.
Before formalizing the agreement, IVI RMA conducted internal validations of the technology within its andrology laboratories to assess whether results derived from stabilized samples could be interpreted within the organization's established analytical frameworks.
According to both companies, the assessments showed that the stabilized samples produced data consistent with the standards IVI RMA applies across its network. For an organization known for its methodical approach to technology adoption, the outcome marks a significant development: a home-collection pathway capable of integrating into the same diagnostic system used for in-clinic patients.
"What interested us about this collaboration was not simply the shift to home collection but the opportunity to modernize part of the diagnostic pathway that has resisted change for decades. Our teams approached the evaluation the way we do with any technology that might influence patient care-methodically and with a focus on reproducibility," said Glenn Proctor, Regional Vice President of IVI RMA North America. "Sapyen's model fits within the integrity of our lab systems while giving patients a more flexible, less burdensome way to begin the fertility process. The partnership allows us to expand access in a way that still reflects the standards we hold ourselves to, and that combination is rare in this space."
"IVI RMA's evaluation was anchored in laboratory integrity, and that process guided the outcome," said Ash Ramachandran, Chief Executive Officer of Sapyen. "But the significance of this partnership is larger than validation-it reflects a shift in how male fertility will be handled going forward. Clinics have been looking for a way to reconcile flexibility with accuracy; this collaboration shows that the two can finally coexist."
The rollout will begin across IVI RMA's West Coast clinics, with expansion planned as laboratory pathways and clinician training progress.
For an industry in which male diagnostics have historically lagged behind broader innovations, the collaboration offers a model for reconciling home-based access with the standards of clinical practice - a combination likely to influence how other networks approach male fertility testing.
About IVI RMA North America
IVI RMA North America, comprising Reproductive Medicine Associates, Boston IVF, and Toronto-based TRIO, spans 24 IVF laboratories and has helped women and couples achieve pregnancies which have led to the birth of over 220,000 babies to date. Pioneers in innovative care, including PGT-A, single embryo transfer, fertility preservation, LGBTQ+ care, and more, the network has published over 1,000 papers which have pushed the fertility industry forward. IVI RMA North America is part of IVI RMA Global, the world's leading Reproductive Medicine group committed to providing evidence-based fertility solutions to patients seeking treatment anywhere in the world. IVI RMA Global employs nearly 6,000 people across 200+ fertility clinics in 15 countries. Learn more at rmanetwork.com and ivirma.com.
About Sapyen
Sapyen is the global leader in home male fertility diagnostics, pioneering solutions that make sperm testing accurate, affordable, and convenient. Its patent-pending SPX72 medium extends semen viability from 1 hour to 72 hours, enabling home collection and secure delivery to CLIA-certified partner laboratories for lab-grade analysis. Sapyen's test kits, starting at $149, provide comprehensive insights-from semen analysis to advanced assays such as DNA fragmentation and DNA Methylation-bringing lab-grade diagnostics directly to patients' homes.
Media Contact
Ash Ramachandran
ash@sapyen.co
https://www.sapyen.co/
SOURCE: Sapyen
View the original press release on ACCESS Newswire